Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imfinzi and Lenvima in Advanced and Metastatic Hepatocellular Carcinoma
NCT04443322Recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Open-label trial of durvalumab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Started Sep 2020; status: recruiting.
02
Drugs
durvalumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04443322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443322.